

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

November 28, 2018

Nicholas DeVito Chief Executive Officer Marizyme, Inc. 2295 Towne Lake Parkway Suite 116-290 Woodstock, GA 30189

Re: Marizyme, Inc.

Amendment No. 2 to Registration Statement on Form 10-12G

Filed November 19, 2018

File No. 000-53223

Dear Mr. DeVito:

We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Amendment No. 2 to Form 10-12G

<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>
<u>Results of Operations</u>

Operating Expenses, page 36

1. Refer to your response to our prior comment 2 and your revised disclosures. Your response states that Operating Expenses are primarily administrative. The revised disclosure states that the increase in operating expenses was primarily the result of rising administrative expenses for professional services related to your required public company filings. However, the income statement includes a line item for operating expenses and a separate line item for administrative expenses. Therefore, revise your disclosure to explain both the change in the operating expenses line item as well as the change in the administrative expenses line item.

Nicholas DeVito Marizyme, Inc. November 28, 2018 Page 2

Note 8. Assets and Liabilities Held for Sale, page F-12

2. With regard to prior comment 6, provide us your computation of the net book equity per share at June 30, 2018 and show how that amount supports the carrying value of your investment in GBS Software AG.

Form 10-Q for the Quarterly Period Ended September 30, 2018

Statements of Operations, page 5

3. Please tell us why the statements of operations and the statements of cash flows do not reflect discontinued operations for the spun-off assets. Refer to ASC 505-60-45-1 and ASC 205-20-50-5B(c).

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Vanessa Robertson at (202) 551-3649 or Lisa Vanjoske at (202) 551-3614 if you have questions regarding comments on the financial statements and related matters. Please contact Tonya K. Aldave at (202) 551-3601 or J. Nolan McWilliams at (202) 551-3217 with any other questions.

Sincerely,

Division of Corporation Finance Office of Healthcare & Insurance

cc: Paul C. Levites, Esq.